Powered by RND
PodcastyWiadomościBeyond Biotech - the podcast from Labiotech

Beyond Biotech - the podcast from Labiotech

Labiotech
Beyond Biotech - the podcast from Labiotech
Najnowszy odcinek

Dostępne odcinki

5 z 154
  • Persica Pharmaceuticals is treating the cause of chronic lower back pain, not just the symptoms
    The World Health Organization reports that more than 600 million people suffer from lower back pain globally, making it the leading cause of disability worldwide. Chronic lower back pain – where the pain persists for more than 3 months – develops in between 5 and 10% of all lower back pain cases, with life-altering impacts for patients.And that’s where today’s guest, Steve Ruston, of Persica Pharmaceuticals comes in. Persica is developing a groundbreaking and transformative treatment for chronic Low Back Pain. Persica is targeting the cause of chronic lower back pain: the underlying bacterial infection. Unlike conventional approaches that manage symptoms, Persica’s drug enables the infection to clear, reducing inflammation, pain and disability at the source.1:20     Introducing Steve Ruston of Persica Pharmaceuticals3:53     Lessons learnt from developing blockbuster drugs6:35     Global experiences in the biopharma industry8:32     Persica Pharmaceuticals and its mission10:26   Collaborations with a network of partners11:48   A non-opioid approach to addressing lower back pain13:35   Treating the cause, not the symptoms15:05   How Persica’s treatment work18:59   Practical impacts of Persica’s treatment21:07   Identifying patients for cLBP treatment23:24   How Persica is changing the treatment landscape28:10   Regulatory hurdles to overcome34:37   Securing funding for Persica’s innovation36:16   The future of treating painInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?Developing non-opioid pain drugsRedefining chronic pain treatment
    --------  
    38:29
  • Humacyte: Saving lives with lab-grown blood vessels in conflict zones
    Trauma surgeons in Ukraine operating theaters saved lives and limbs thanks to the innovative lab-grown blood vessels from US biotech, Humacyte.Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and regenerative, with the goal of treating a wide variety of diseases, injuries, and chronic conditions.This week I had the chance to speak to Humacyte founder, President and Chief Executive Laura Niklason about the company she has built, the science she is driving forward, and the real-world applications for Humacyte’s lab-grown blood vessels in some of the most devastating and dangerous conflicts.1:00     Introducing Laura Niklason4:50     Humacyte and its mission6:27     Competitive landscape7:45     Partnering for scale9:49     How to grow blood vessels in the lab11:47   Implanting the vessels13:32   Human vessels vs synthetic vessels15:10   The manufacturing process16:23   Overcoming skepticism, demonstrating value19:01   Navigating the regulatory approval process21:17   The role of the Department of Defense in innovative biotech22:30   Using Humacyte vessels in the field23:20   Humacyte vessels in the Ukraine War28:22   Lessons from the Ukraine War30:09   Goals for the coming years33:35   Scaling manufacturingInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic:Current trends & innovations in 3D organoidsThe future of organ transplants: Xenotransplantation, 3D bioprinting and stem cells
    --------  
    36:27
  • Special Episode: The 2025 BIO International Convention
    Much of the attention of the biotech industry has been focused on the city of Boston this week as the annual BIO International Convention hit town. BIO is the world’s largest partnering conference for the biopharma industry and thousands of innovators, out-licensors, venture capitalists, top pharma dealmakers, thought leaders and more than a few politicians gathered for three days of meetings, presentations, and networking.In this week’s episode we meet three innovators on the floor in Boston and find out what their BIO experience has been like, how their partnering meetings have progressed, what’s surprised them, and how it feels to be in the middle of the biggest biopharma conference of the year.---This week’s episode is brought to you by Inpart.If you're in life sciences, you know how complex partnering can be — whether you're searching for the right innovation, managing a portfolio of alliances, or navigating the path from first meeting to signed deal. That’s where Inpart comes in.Inpart is a platform built specifically for partnering in pharma, biotech, and research. It brings together the tools, data, and workflows teams need to scout opportunities, manage submissions, and keep partnerships on track: from discovery through to alliance execution.Whether you're on the lookout for external innovation or trying to simplify internal coordination, Inpart helps you partner more strategically and move faster.To learn more, visit inpart.io.---0:00  The ‘Beyond Biotech’ BIO International Convention Special01:58   Purespring Therapeutics CEO Haseeb Ahmad14:10   Inpart Chief Business Officer Patrick Speedie25:44  Newbiologix CEO Igor FischInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter---To dive deeper into the topic: The hottest biotech companies in the Boston areaNine tips to succeed in pharma-biotech partnershipsThe ABC of biotech partnerships
    --------  
    38:20
  • Alex Telford on AI, drug discovery, digital twins, and the most interesting questions in biotech
    What are the most interesting questions in biotech, and is it even possible to find answers to those questions?Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco Bay Area. His blog post, 'Some questions about biotech that I find interesting' provoked conversations online as readers engaged with questions about topics as diverse as the impacts of regulation, the role of serendipity in drug discovery, clinical trial failure rates, and the best structure for governing large pharmaceutical companies companies.In this episode Alex explains the work he is doing at Convoke before opening the door to his insatiable curiosity about the biotech industry.01:17               Introducing Alex Telford04:28              The business of biotech09:02              Convoke and its mission14:21               ‘Some questions about biotech that I find interesting’16:57               Why founders should be writing and blogging18:44               Generating good questions about biotech20:50              AI and its role in drug discovery26:21               Will AI mean the end of serendipitous drug discovery?28:15               Regulatory challenges for biotech34:17               Is the FDA a net positive or net negative for the industry?36:56              The unanswerable questions in biotech39:00              Digital twins in biotechnology42:15               The next interesting questions in biotechInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 12 AI drug discovery companies you should know aboutDoes the FDA need to tighten its grip on drug trials in the U.S.?2025 predictions: Which trends are set to shape the biotech industry this year?
    --------  
    46:26
  • Corporate venture capital and biotechnology in 2025: challenges, opportunities, and threats
    When biotechs start fundraising they regularly turn to the venture capital market seeking investment. The pool of VC money can be large, and part of that pool is corporate venture capital. Backed by firms keen to identify the next big thing in biotechnology, corporate VC money can be an attractive way for biotechs to raise funds privately while benefiting from the support and expertise of corporate supporters.This week I talked with Paolo Di Giorgio and Regina Hodits of Angelini Ventures, the corporate VC arm of Angelini Industries, itself the parent company of Angelini Pharma. Paolo and Regina lay out their perspective on the current fundraising landscape, identify the trends and opportunities for innovative biotechs in Europe, and walk me though the biggest threats to the biotech investment market they see on the near horizon.01:15               Introducing Paolo Di Giorgio04:00               Introducing Regine Hodits05:31               The mission of Angelini Ventures09:55               Focus areas and investments in early stage science14:30               The state of venture capital investment in biotech in 202517:48               Why biotechs should favor corporate venture capital20:43               Why networking and expertise matter in fundraising26:05               The therapeutic areas and modalities that are hot right now29:19               Geographic focus for corporate venture capital33:28               Threats on the horizon36:36               What keeps a corporate VC investor up at night?40:13               Keep in touch with Angelini VenturesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter
    --------  
    42:12

Więcej Wiadomości podcastów

O Beyond Biotech - the podcast from Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Strona internetowa podcastu

Słuchaj Beyond Biotech - the podcast from Labiotech, Global News Podcast i wielu innych podcastów z całego świata dzięki aplikacji radio.pl

Uzyskaj bezpłatną aplikację radio.pl

  • Stacje i podcasty do zakładek
  • Strumieniuj przez Wi-Fi lub Bluetooth
  • Obsługuje Carplay & Android Auto
  • Jeszcze więcej funkcjonalności
Media spoecznościowe
v7.20.1 | © 2007-2025 radio.de GmbH
Generated: 7/5/2025 - 8:06:11 PM